Novo Nordisk
Q3 2022 Earnings Call
Nov 02, 2022, 8:00 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Good day, and thank you for standing by. Welcome to Q3 2022 Novo Nordisk A/S earnings conference call. [Operator instructions] I would now like to hand the conference over to your speaker today, CEO, Lars Fruergaard Jorgensen. Please go ahead.
Lars Fruergaard Jorgensen -- President and Chief Executive Officer
Thank you, operator. Welcome to this Novo's earnings call for the first nine months of 2022 and the outlook for the year. My name is Lars Fruergaard Jorgensen, and I'm the CEO of Novo Nordisk. With me today, I have executive vice president and head of commercial strategy and corporate affairs, Camilla Sylvest; executive vice president and head of North America operations, Doug Langa; executive vice president and head of development, Martin Holst Lange; and finally, chief financial officer, Karsten Munk.
All of us will be available for the Q&A session. Today's announcement and the slides for this call are available on our website, novonordisk.com. Please note that the call would be webcast live, and a recording will be made available on our website as well. Call is scheduled to last for one hour.
Please turn to the next slide. The presentation is structured as outlined on Slide 2. Please note that all sales and operating profit statements will be at constant exchange rates, unless otherwise specified. The Q&A session will begin in about 25 minutes.
Please turn to Slide 3. As always, I need to advise you that this call will contain forward-looking statements. These are subject to risks and uncertainties that could cause actual results to differ materially from expectations. For further information on the risk factors, please see the company's filings for the first nine months of 2022 and the slides prepared for this presentation.
Please turn to the next slide. In the first nine months of 2022, we delivered double-digit sales and operating profit growth, which has enabled us to raise our outlook for the full year. I would like to start this call by going through the performance highlights across our operations before handing over the word to my colleagues. We continue to make progress across all dimensions of service and sustainability.
Our carbon emissions decreased by 18% compared to the first nine months of 2019, and we continue to reach even more patients compared to the same period last year. Within our aspiration of being a sustainable employer, we expanded the number of women in senior leadership positions to 38% compared to 36% by the end of September 2021. Within R&D, we are pleased with the encouraging phase 2 data with CagriSema in Type 2 diabetes, as well as the successful completion of the pivotal phase 3 program for once-weekly insulin icodec. Both support our aspiration of further raising the innovation bar for diabetes treatments.